Myriad Women's Health provides actionable information that guides critical and timely health decisions.
Whether it’s starting a family...
Missy & Yan
Myriad Foresight Carrier Screen
patients, with their daughter Sonya
Identify couples at risk to pass down serious, prevalent, clinically-actionable inherited conditions.Learn more >
Myriad Prequel Prenatal Screen
patient, carrying her first child
Get reliable results, the first time with our noninvasive prenatal screen (NIPS).Learn more >
...or evaluating risk for cancer.
Hereditary Cancer Screen
patient, pictured with her grandmother
Hereditary Cancer Test
Help patients get ahead of cancer with our hereditary cancer testLearn more >
The clinical impact of our genetic products help elevate the standard of care.
86% of affected
pregnancies no longer missed
86% of affected pregnancies detected by expanded carrier screening (ECS) are missed when screening for cystic fibrosis and spinal muscular atrophy alone.1Learn how ECS detects more at-risk couples for serious conditions >
76% of couples
76% of couples found by ECS to be at risk for severe or profound conditions pursued alternative reproductive actions such as prenatal diagnosis or IVF with preimplantation genetic diagnosis.2
The false positive rate of noninvasive prenatal screening (NIPS) is 100x lower than serum screening in patients <35 years old.3Learn why NIPS leads to fewer unnecessary invasive procedures >
50% of hereditary cancers are non BRCA1/2
At least 50% of hereditary cancers are caused by genes other than BRCA1 and BRCA2.4Learn how to identify more patients at high risk for hereditary cancer >
Myriad Complete™ provides support for providers and patients throughout the screening process.
We provide resources to help you educate your patients about Myriad products.
We offer a comprehensive program to make genetic products accessible for more of your patients.
We deliver screening and testing results effectively and thoroughly so you can focus on care plans.
We provide consults from genetic counselors tailored to help your patient understand their results.
Your patients depend on you for
your advice and answers.
So you need someone you can lean on. Someone who is committed to your patients. We help you offer meaningful genetic screening and testing services and support your practice along the way.
Together, with Myriad
for you and your patients
- Hogan et al. Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification. Clinical Chemistry 2018; doi:10.1373/clinchem.2018.286823
- Ghiossi, C.E., Goldberg, J.D., Haque, I.S. et al. J Genet Counsel (2017). https://doi.org/10.1007/s10897-017-0160-1.
- Norton, M. et al Cell free DNA analysis for noninvasive examination of trisomy. The New England Journal of Medicine April 2015; 372: 1589-1597.
- BRCA1/BRCA2 Frequency: Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014.